These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18034766)

  • 21. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A.
    Sørensen B; Persson E; Ingerslev J
    Br J Haematol; 2007 Apr; 137(2):158-65. PubMed ID: 17391496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays.
    Radtke KP; Griffin JH; Riceberg J; Gale AJ
    J Thromb Haemost; 2007 Jan; 5(1):102-8. PubMed ID: 17059431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Temporal changes in clot lysis and clot stability following tranexamic acid in cardiac surgery.
    Tang M; Wierup P; Rea CJ; Ingerslev J; Hjortdal VE; Sørensen B
    Blood Coagul Fibrinolysis; 2017 Jun; 28(4):295-302. PubMed ID: 27607599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
    Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
    Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibrinolysis in trauma patients: wide variability demonstrated by the Lysis Timer.
    Roullet S; Weinmann L; Labrouche S; Gisbert-Mora C; Biais M; Revel P; Freyburger G
    Scand J Clin Lab Invest; 2019; 79(1-2):136-142. PubMed ID: 30861350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A.
    Rea CJ; Foley JH; Ingerslev J; Sørensen B
    J Thromb Haemost; 2011 Mar; 9(3):510-6. PubMed ID: 21155966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clot formation and fibrinolysis assays reveal functional differences among hemostatic agents in hemophilia A plasma.
    Holle LA; Pantazis JC; Turecek PL; Wolberg AS
    Res Pract Thromb Haemost; 2024 Jan; 8(1):102337. PubMed ID: 38426025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasmin thrombelastography rapidly identifies trauma patients at risk for massive transfusion, mortality, and hyperfibrinolysis: A diagnostic tool to resolve an international debate on tranexamic acid?
    Barrett CD; Moore HB; Vigneshwar N; Dhara S; Chandler J; Chapman MP; Sauaia A; Moore EE; Yaffe MB
    J Trauma Acute Care Surg; 2020 Dec; 89(6):991-998. PubMed ID: 33230046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the in-vivo effect of two tranexamic acid doses on fibrinolysis parameters in adults undergoing valvular cardiac surgery with cardiopulmonary bypass - a pilot investigation.
    Zhou ZF; Zhai W; Yu LN; Sun K; Sun LH; Xing XF; Yan M
    BMC Anesthesiol; 2021 Feb; 21(1):33. PubMed ID: 33530942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.
    Lisman T; Mosnier LO; Lambert T; Mauser-Bunschoten EP; Meijers JC; Nieuwenhuis HK; de Groot PG
    Blood; 2002 Jan; 99(1):175-9. PubMed ID: 11756168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using antifibrinolytics in the peripartum period - concern for a hypercoagulable effect?
    Ahmadzia HK; Lockhart EL; Thomas SM; Welsby IJ; Hoffman MR; James AH; Murtha AP; Swamy GK; Grotegut CA
    J Neonatal Perinatal Med; 2017; 10(1):1-7. PubMed ID: 28304315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of resuscitation fluids, fresh frozen plasma and antifibrinolytics on fibrinolysis in a thrombelastography-based, in-vitro, whole-blood model.
    Kostousov V; Wang YW; Cotton BA; Wade CE; Holcomb JB; Matijevic N
    Blood Coagul Fibrinolysis; 2013 Jul; 24(5):489-97. PubMed ID: 23406662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A.
    Lisman T; de Groot PG; Lambert T; Røjkjaer R; Persson E
    J Thromb Haemost; 2003 Oct; 1(10):2175-8. PubMed ID: 14521601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa.
    Sørensen B; Ingerslev J
    J Thromb Haemost; 2004 Jan; 2(1):102-10. PubMed ID: 14717973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII.
    Demers M; Aleman MM; Kistanova E; Peters R; Salas J; Seth Chhabra E
    J Thromb Haemost; 2022 Jul; 20(7):1674-1683. PubMed ID: 35466511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein.
    Peters RT; Toby G; Lu Q; Liu T; Kulman JD; Low SC; Bitonti AJ; Pierce GF
    J Thromb Haemost; 2013 Jan; 11(1):132-41. PubMed ID: 23205847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of a plasmin generation assay to define pharmacodynamic effects of tranexamic acid in women undergoing cesarean delivery.
    Miszta A; Ahmadzia HK; Luban NLC; Li S; Guo D; Holle LA; Berger JS; James AH; Gobburu JVS; van den Anker J; de Laat B; Wolberg AS
    J Thromb Haemost; 2021 Jan; 19(1):221-232. PubMed ID: 33001565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation.
    Taketomi T; Szlam F; Bader SO; Sheppard CA; Levy JH; Tanaka KA
    Blood Coagul Fibrinolysis; 2008 Mar; 19(2):135-41. PubMed ID: 18277134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII.
    Yoshioka A; Nishio K; Shima M
    Haemostasis; 1996; 26 Suppl 1():139-42. PubMed ID: 8904189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Point-of-care testing for tranexamic acid efficacy: a proof-of-concept study in cardiac surgical patients.
    Yoshii R; Takahashi Y; Tanaka KA; Kawajiri H; Sawa T; Amaya F; Ogawa S
    Br J Anaesth; 2024 Jun; 132(6):1211-1218. PubMed ID: 38677950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.